Investigational drug · Phase 3
Anselamimab
Also called: CAEL-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for AL Amyloidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Anselamimab"
First trial start
2020
Aug 25, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Anselamimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- AL Amyloidosis
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Anselamimab" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)Pivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04512235 · 281 participants · Start Nov 3, 2020 · Primary completion Apr 8, 2025
Drug: CAEL-101; cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen · For: AL Amyloidosis
Sites: Scottsdale, Arizona; Duarte, California; Palo Alto, California · 110 sites in all
- A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL AmyloidosisCompleted
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT04304144 · 25 participants · Start Mar 18, 2020 · Primary completion Nov 14, 2023
Drug: CAEL-101; SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) and 1 more · For: AL Amyloidosis
Sites: Stanford, California; Detroit, Michigan; Cleveland, Ohio
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue InvolvementNot yet recruiting
Stanford UniversityAcademic, hospital or other
NCT07615270 · 5 participants (planned) · Start Sep 2026 · Primary completion Jul 2028
Drug: Anselamimab · For: AL Amyloidosis
Sites: Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.
Valent J, Zonder J, Swenson ES, et al. · Eur J Cancer 2026
- Clearing perivascular light chain-derived amyloid to counteract aging-associated decline in liver regeneration.
Zhang Y, Yang Y, He G, et al. · Cell Rep 2026
- Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials.
Wang X, Fontana M, Claggett B, et al. · Circulation 2026
- Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Wechalekar AD, Dispenzieri A, Sanchorawala V, et al. · J Clin Oncol 2026
- 1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis.
Fu J, Hughes MS, Kalantarov GF, et al. · Blood 2026
- Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Wechalekar AD, Dispenzieri A, Sanchorawala V, et al. · J Clin Oncol 2026
Also in development for AL Amyloidosis
- and dexamethasonePhase 32 trials
AstraZeneca · AL Amyloidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.